Cell Impact Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Cell Impact şirketinin toplam hissedar öz sermayesi SEK259.0M ve toplam borcu SEK19.7M olup, bu da borç-öz sermaye oranını 7.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK315.0M ve SEK56.0M dir.

Anahtar bilgiler

7.6%

Borç/özkaynak oranı

SEK 19.73m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 22.62m
Eşitlik	SEK 259.01m
Toplam yükümlülükler	SEK 56.00m
Toplam varlıklar	SEK 315.01m

Son finansal sağlık güncellemeleri

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Recent updates

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

May 13

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Jan 14

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

May 09

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Feb 21

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

Dec 27

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CI 'nin kısa vadeli varlıkları ( SEK97.2M ) kısa vadeli yükümlülüklerini ( SEK28.2M ) aşıyor.

Uzun Vadeli Yükümlülükler: CI şirketinin kısa vadeli varlıkları ( SEK97.2M ) uzun vadeli yükümlülüklerini ( SEK27.8M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CI şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: CI şirketinin borç/öz sermaye oranı son 5 yılda 2.1% seviyesinden 7.6% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CI şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CI un, serbest nakit akışı her yıl % 25.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Cell Impact Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

Recent updates

Chairman of the Board exercised options to buy kr76k worth of stock.

Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024

Director recently bought kr125k worth of stock

Second quarter 2024 earnings released

Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030

Cell Impact Adds Sealing as A New Part of Production Process

New major risk - Share price stability

First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)

Cell Impact AB (Publ) Announces Board and Committee Changes

Director recently bought kr91k worth of stock

Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)

Cell Impact AB (Publ) Appoints Henrik Jackman as Chief Application Engineer

Chief Executive Officer recently bought kr50k worth of stock

Cell Impact AB (publ) Announces CEO Changes

New major risk - Shareholder dilution

Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFO

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)

Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023

New major risk - Market cap size

Cell Impact AB (publ) Announces Anna Frick Will Leave the Board

Chief Executive Officer recently bought kr101k worth of stock

Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028

Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product Development

New major risk - Share price stability

Chief Executive Officer recently bought kr50k worth of stock

Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?

Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)

Cell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024

Is Cell Impact (STO:CI) Using Debt In A Risky Way?

No independent directors

Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)

Second quarter 2022 earnings released

Cell Impact AB (publ) PUBL SHARE AK B to Be Deleted from Other OTC

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings released: kr1.35 loss per share (vs kr0.88 loss in FY 2020)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Cell Impact AB (publ) to Report Q2, 2022 Results on Aug 25, 2022

Third quarter 2021 earnings released

Second quarter 2021 earnings released

Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn Situation

First quarter 2021 earnings released

Cell Impact AB (publ) Receives SEK 42 Million Order from Plug Power for New Production Line and Flow Plates

Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%

Full year 2020 earnings released: kr0.85 loss per share (vs kr1.45 loss in FY 2019)

New 90-day high: kr49.70

Cell Impact Appoints Forrest Zhang as Country Manager in China, Effective May 3, 2021

How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?

New 90-day high: kr29.30

New 90-day high: kr29.00

Third quarter 2020 earnings released: kr0.12 loss per share

New 90-day low: kr21.35

Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million.

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin